Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology
• Oncology

Background:

• Cancer immunotherapy shows promise but faces challenges like poor T-cell activation, immunosuppressive tumor microenvironments (TME), and toxicity.
• Pyroptosis, a pro-inflammatory programmed cell death, releases cytokines and activates immune cells, offering a potential solution to these limitations.

Purpose of the Study:

• To review nanotechnology-based strategies for inducing pyroptosis to enhance cancer immunotherapy.
• To classify pyroptosis-inducing nanomaterials into distinct therapeutic platforms.
• To elucidate mechanisms of TME modulation via pyroptosis and identify future challenges.

Main Methods:

• Classification of pyroptosis-inducing nanomaterials into five therapeutic platforms: immune checkpoint inhibitors, vaccine adjuvants, oncolytic virus-coupled systems, innate immune sensitizers, and multi-modal hybrids.
• Elucidation of mechanisms by which pyroptosis reshapes the TME through immunogenicity and bystander immune cell activation.
• Identification and discussion of challenges including tumor resistance, nanoparticle delivery, and cytokine storm risks.

Main Results:

• Nanotechnology-enabled pyroptosis induction presents five combinatorial therapeutic platforms for potentiating immunotherapy.
• Pyroptosis effectively reshapes the TME by enhancing immunogenicity and activating immune cells.
• Key challenges remain, including pyroptosis resistance in tumors, nanoparticle biodistribution, and managing cytokine release.

Conclusions:

• Integrating nanotechnology with pyroptosis induction offers a promising strategy to overcome current cancer immunotherapy limitations.
• This synergistic approach facilitates precision immune modulation by enhancing T-cell responses and modifying the TME.
• Addressing identified challenges is crucial for the successful clinical translation of pyroptosis-nanotechnology synergies.